August 9, 2010 – According to Millennium Research Group (MRG), a medical technology market research company, Invatec has traditionally held a much stronger position in the European percutaneous transluminal angioplasty (PTA) balloon catheter market compared to the United States. Nonetheless, sales of Invatec's PTA balloon catheters picked up in the United States in the first quarter of 2010, according to MRG's Peripheral Vascular Marketrack study, coinciding with Medtronic's announcement it would purchase the company. Further success of the Invatec product lines in the United States will be bolstered by Medtronic's established sales and marketing efforts.
Invatec, whose purchase by Medtronic was finalized in April, is known for its high-quality PTA product line for the treatment of peripheral artery disease, especially in Europe, where the company was the fourth-leading competitor in the PTA balloon catheter market in 2009.
Conversely, Invatec products captured approximately 5 percent of the U.S. PTA balloon catheter market in 2009, where it offered only a selection of its products. Medtronic's acquisition of Invatec is expected to benefit both companies and has the potential for a synergistic relationship -- with Medtronic broadening its peripheral vascular product line and Invatec expanding its presence in the US market.
"Invatec has traditionally maintained only a small presence in the U.S. PTA balloon catheter market, meaning significant opportunity exists for Medtronic to expand the presence of these product lines in the U.S.," said Stephanie Labelle, manager of the cardiovascular division at MRG.
"The Invatec product line will benefit from Medtronic's existing relationships with physicians using its drug-eluting coronary stents and aortic stent grafts, therefore expanding Invatec's penetration into U.S. facilities. In addition, Medtronic may consider bringing additional Invatec products to the U.S. marketplace that would further increase the company's share of the peripheral vascular device market, including the In.Pact Admiral drug-eluting balloon, the Cristallo Ideale carotid stent, and the innovative Mo.Ma Ultra embolic protection device, which are currently available in Europe, and would further increase the company's competitiveness in the U.S. peripheral vascular device market."
MRG's Peripheral Vascular Marketrack project gathers facility level procedure and product usage data on treatments for peripheral artery disease. Data is collected on a monthly basis in the United States and a quarterly basis in Europe from interventional radiology labs, interventional cardiology labs, and operating rooms throughout the United States and Europe. Marketrack subscribers receive thousands of data points, including usage (units, average selling price, and revenue), procedure, competitor, and brand information.
For more information: www.MRG.net
June 13, 2024 
